



## **Thrombolytic Science Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as a Non-Executive Board Member**

*Former Head of Global R&D for Merck Serono  
and Head of Global Medical Affairs of Bristol-Myers Squibb  
Brings Clinical Development, Fundraising and M&A Experience*

CAMBRIDGE, Mass., USA, November 14, 2017 / [B3C newswire](#) / –Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, formerly President and CEO of Dimension Therapeutics, Inc., as a non-executive board member. Dr. Jenkins brings over 25 years of global pharmaceutical industry experience to TSI's Board of Directors.

"Dr. Jenkins has a proven track record of successfully translating exciting science from bench to bedside." said Michael Woehler, PhD, Chairman of TSI. "We are pleased to welcome Annalisa to our board at an important time for the company, where her extensive and broad experience in all aspects of biotechnology, drug development and M&A will prove invaluable".

TSI recently completed of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy mimicking nature's safe and efficient fibrinolytic system, which is aimed at the treatment of clot-induced diseases. The first-in-man randomized, double-blind, placebo-controlled study demonstrated the overall safety and tolerability of TS01 in healthy adults. The Company is now preparing to enter human proof of concept trials in ischemic stroke and myocardial infraction.

"I look forward to Dr. Jenkins' contributions in advancing TS01 into phase 2 clinical trials," said Alexis C. Wallace, Chief Executive Officer of TSI "and ensuring patient access to TSI's pioneering fibrinolytic solution through biopharma collaborations."

Prior to joining TSI's board of directors, Dr. Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx Pharmaceutical in November 2017. Dr. Jenkins previously held multiple leadership positions, including executive vice president, head of Global Research and Development for Merck Serono, where she led Global Medical Affairs and Quality, and was a member of Merck Serono's Pharmaceutical Executive Committee. Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs. During her tenure at BMS, Dr. Jenkins played a key role in the development, approval, and/or commercialization of products in multiple therapeutic areas, including cardiology, immunology, immunology and infectious diseases. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon

Lieutenant Commander. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew's Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Dr. Jenkins chairs the boards of Cell Medica, Silence Therapeutics and Vium, and is a Director on the boards of OncoSec, Ardelyx, Phesi, iOx, and Cocoon. She is also a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), serves on the board of the Center for Talent Innovation (UK), and is on the Advisory Panel of the Healthcare Businesswomen's Association.

### **About Stroke**

Each year, strokes affect 15 million people worldwide. In the United States, it is the leading cause of long-term disability and the fifth-leading cause of death, costing the healthcare system in excess of \$73 billion each year. Approximately 90 percent of all strokes are caused by blood clots, for which there is no effective and safe treatment.

### **About TS01**

TS01 is a proprietary new-generation, clot-dissolving therapy for the treatment of patients with ischemic stroke and other thrombotic diseases. HisproUK, TS01's main component, is a proprietary, rationally designed, single-site mutant of native proUK. TS01 selectively targets occlusive clots that cause strokes and heart attacks.

### **About TSI**

TSI is a privately-held vascular health and biotechnology company currently developing a new-generation bio-inspired clot-dissolving therapy. TSI intends to develop treatments for ischemic stroke, heart attacks and other clot-induced diseases. TSI's technology is based upon pioneering earlier work on proUK by the Vascular Research Laboratory.

For more information, please visit [tsillc.net](http://tsillc.net).

###

### Corporate Contact

Alexis Wallace, M.Sc.Eng., MBA

President & CEO

[awallace@tsillc.net](mailto:awallace@tsillc.net)